Page last updated: 2024-09-03

gefitinib and gallic acid

gefitinib has been researched along with gallic acid in 1 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(gallic acid)
Trials
(gallic acid)
Recent Studies (post-2010) (gallic acid)
5,2315662,9194,793422,579

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)gallic acid (IC50)
Urokinase-type plasminogen activatorHomo sapiens (human)6.6
Tissue-type plasminogen activatorHomo sapiens (human)6.6
Plasminogen activator inhibitor 1Homo sapiens (human)6.6
Urokinase-type plasminogen activatorMus musculus (house mouse)6.6
72 kDa type IV collagenaseHomo sapiens (human)4.03
MatrilysinHomo sapiens (human)4.03
Dipeptidyl peptidase 4Homo sapiens (human)4.65
Alpha-synucleinHomo sapiens (human)4.43
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)4.03
Polypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)1.37
Alpha-(1,3)-fucosyltransferase 7Homo sapiens (human)4.03
CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)4.03

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Choi, JW; Hua, TN; Jeong, Y; Kim, HW; Kim, KW; Kim, MK; Phan, AN; Rho, JK; Vo, VT1

Other Studies

1 other study(ies) available for gefitinib and gallic acid

ArticleYear
Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Oncotarget, 2016, Aug-23, Volume: 7, Issue:34

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gallic Acid; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Xenograft Model Antitumor Assays

2016